8-K: Verrica Pharmaceuticals Reports $3.4 Million in YCANTH Revenue, Driven by Increased Demand in Q1 2025

Verrica Pharmaceuticals announces its Q1 2025 financial results, highlighting $3.4 million in YCANTH revenue and progress in its late-stage pipeline.

Summary

• Verrica Pharmaceuticals reported $3.4 million in YCANTH revenue for the first quarter of 2025.
• This revenue reflects increasing demand, with over 10,000 applicator units dispensed, a 16.7% increase over Q4 2024.
• The company's late-stage pipeline is advancing, with an end-of-Phase 2 meeting completed with the FDA for VP-315 (basal cell carcinoma).
• Verrica is also progressing towards initiating a global Phase 3 program for common warts (VP-102/YCANTH) with Torii Pharmaceutical.
• The net loss for Q1 2025 was $9.7 million, or $0.10 per share, compared to a net loss of $20.3 million, or $0.44 per share, for the same period in 2024.
• Non-GAAP net loss was $7.8 million, or $0.08 per share, compared to $17.8 million, or $0.38 per share, for Q1 2024.
• As of March 31, 2025, Verrica had $29.6 million in cash and cash equivalents.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to increased revenue, progress in clinical trials, and reduced losses, but tempered by the remaining net loss and decreased cash reserves.

Positives

• YCANTH revenue increased to $3.4 million in Q1 2025, indicating strong demand.
• Dispensed applicator units increased by 16.7% compared to the previous quarter, showing growth in product usage.
• The company is advancing its pipeline with VP-315 and YCANTH for common warts.
• Net loss and non-GAAP net loss have significantly decreased compared to the same period last year.
• Noah L. Rosenberg, M.D., was appointed as Chief Medical Officer.
• Dr. Gavin Corcoran was appointed to the Board of Directors.

Negatives

• The company still reported a net loss of $9.7 million for the quarter.
• Cash and cash equivalents decreased from $46.3 million at the end of 2024 to $29.6 million as of March 31, 2025.
• Interest income decreased due to a lower cash balance.

Risks

• The company's ability to sustain revenue growth and the alignment between dispensed applicator units and revenue going forward is uncertain.
• Clinical development of product candidates involves risks and uncertainties.
• Market conditions could impact the commercialization of YCANTH.
• Satisfaction of customary closing conditions related to the proposed public offering could impact results.

Future Outlook

Verrica expects the closer alignment between dispensed applicator units and revenue to continue going forward and is looking to build on the momentum in the second quarter. The company also plans to initiate a global Phase 3 program of YCANTH for the treatment of common warts and advance VP-315 for basal cell carcinoma.

Management Comments

• Dr. Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica, stated that the focused commercialization strategy is helping to drive increased demand for YCANTH.
• Dr. Rieger also mentioned that the company is excited by the strong pull-through from distributors, which translated to $3.4 million in revenue in the first quarter.
• Dr. Rieger noted that Verrica's clinical-stage pipeline continues to advance.

Industry Context

Verrica's focus on dermatology therapeutics, particularly for skin diseases requiring medical interventions, positions it in a growing market. The company's progress with YCANTH and VP-315 addresses unmet needs in molluscum contagiosum and basal cell carcinoma, respectively.

Comparison to Industry Standards

• Comparing Verrica to companies like Cassiopea S.p.A. and Journey Medical Corporation, which also focus on dermatology, Verrica's revenue from YCANTH is a key indicator of its commercial success.
• The decrease in operating expenses, particularly in selling, general, and administrative costs, suggests improved efficiency compared to previous periods and potentially versus industry averages.
• The progress of VP-315 in clinical trials is comparable to other companies developing novel therapies for skin cancers, such as Replimune Group, Inc.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the increased revenue and reduced losses.
• Employees may be affected by changes in compensation and commercial activities.
• Customers (patients) benefit from the availability of YCANTH for molluscum contagiosum.
• Suppliers and distributors are impacted by the demand for YCANTH.

Next Steps

• Verrica plans to announce additional genomic and immune response data for VP-315 in mid-2025.
• The company plans to provide a global development program update for VP-315, including information on the design of the Phase 3 clinical program, in mid-2025.
• Verrica will continue to work with Torii Pharmaceutical to initiate the global Phase 3 program of YCANTH for the treatment of common warts.

Key Dates

Keywords

YCANTH, VP-315, Verrica Pharmaceuticals, Financial Results, Molluscum Contagiosum, Basal Cell Carcinoma, Dermatology, Revenue, Clinical Trials